Evidence map›Paper›PMID 42812850›Full record

ArticleOpen forum infectious diseases2026

Trends in Mortality and the Effects of the Coronavirus Disease 2019 Pandemic on Mortality Among Adult Patients With

Carly Adams, Holly M Biggs, Kelly A Jackson, Joelle Nadle, Susan Petit, Susan M Ray, Ruth Lynfield, Carmen Bernu, Ghinwa Dumyati, Marissa Walsh and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Carly AdamsDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-9220-7169
Holly M BiggsDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-4949-2232
Kelly A JacksonDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0001-5398-0135
Joelle NadleCalifornia Emerging Infections Program, Oakland, California, USA.ORCID https://orcid.org/0009-0008-7874-7135
Susan PetitInfectious Disease Branch, Connecticut Department of Public Health, Hartford, Connecticut, USA.
Susan M RayDepartment of Medicine (Division of Infectious Diseases), Georgia Emerging Infections Program and Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-6327-088X
Ruth LynfieldMinnesota Emerging Infections Program, Minnesota Department of Health, St. Paul, Minnesota, USA.
Carmen BernuMinnesota Emerging Infections Program, Minnesota Department of Health, St. Paul, Minnesota, USA.
Ghinwa DumyatiNew York Emerging Infections Program, University of Rochester Medical Center, Rochester, New York, USA.ORCID https://orcid.org/0000-0002-3634-2841
Marissa WalshNew York Emerging Infections Program, University of Rochester Medical Center, Rochester, New York, USA.
William SchaffnerDepartment of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0002-1375-8078
H Keipp TalbotDepartment of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Lee H HarrisonDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Isaac SeeDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0001-6203-3084

Funding

NCEZID CDC HHS U50 CK000195NCEZID CDC HHS U50 CK000196NCEZID CDC HHS U50 CK000198NCEZID CDC HHS U50 CK000199NCEZID CDC HHS U50 CK000201NCEZID CDC HHS U50 CK000203NCEZID CDC HHS U50 CK000204
6 · The paper itself

Abstract

Background: Trends in Methods: Active, laboratory- and population-based surveillance data from 20 counties (7 states) were used to examine annual, 30-day mortality rates among US adult patients with methicillin-resistant and methicillin-susceptible Results: Overall, SAB mortality was 21%. Annual SAB mortality rates were generally stable prepandemic before increasing by 33% and 41% among HO MRSA and MSSA cases, respectively, and by 49% among CA MRSA cases, but not among HACO or MSSA CA cases, from 2019 through 2021. Among HO cases with recent SARS-CoV-2 infection, annual mortality rates were as high as 75%. Adjusted hazard ratios for recent SARS-CoV-2 infection ranged from 1.9 (95% confidence interval: 1.5-2.3) (HACO MRSA) to 3.0 (95% confidence interval: 2.4-3.7) (HO MSSA). Conclusions: Recent SARS-CoV-2 infection was a significant risk factor for death among patients with SAB during 2020-2022. Strengthening infection prevention efforts in similar respiratory pandemics in the future could help prevent increases in SAB mortality rates.

Indexed as

COVID-19mortalityStaphylococcus aureusStaphylococcus aureus bacteremiatrends

Identifiers

PMID42812850
PMCPMC13622340

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.